Altogether, our results lend support for statewide Medicaid policymakers to expand Medicaid coverage of CGMs for people with T2DM on once-daily insulin per American Diabetes Association guidelines [14, 40, 41] especially given that such an access expansion is projected to be highly cost-effective [42, 43]. The gene discussed is INS; the disease is type 2 diabetes mellitus.